JP2017504567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504567A5 JP2017504567A5 JP2016533043A JP2016533043A JP2017504567A5 JP 2017504567 A5 JP2017504567 A5 JP 2017504567A5 JP 2016533043 A JP2016533043 A JP 2016533043A JP 2016533043 A JP2016533043 A JP 2016533043A JP 2017504567 A5 JP2017504567 A5 JP 2017504567A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- disease
- disorder
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000000509 Estrogen Receptor beta Human genes 0.000 claims description 10
- 108010041356 Estrogen Receptor beta Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000000556 agonist Substances 0.000 description 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361963031P | 2013-11-21 | 2013-11-21 | |
| US61/963,031 | 2013-11-21 | ||
| PCT/US2014/066896 WO2015077611A1 (en) | 2013-11-21 | 2014-11-21 | Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504567A JP2017504567A (ja) | 2017-02-09 |
| JP2017504567A5 true JP2017504567A5 (enExample) | 2017-06-08 |
| JP6431538B2 JP6431538B2 (ja) | 2018-11-28 |
Family
ID=53180206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533043A Active JP6431538B2 (ja) | 2013-11-21 | 2014-11-21 | エストロゲン受容体ベータアイソフォームの選択的アゴニストとしての置換（４’−ヒドロキシフェニル）シクロアルカン化合物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10570077B2 (enExample) |
| EP (1) | EP3071541B1 (enExample) |
| JP (1) | JP6431538B2 (enExample) |
| AU (1) | AU2014352830B2 (enExample) |
| CA (1) | CA2931313C (enExample) |
| WO (1) | WO2015077611A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210340155A1 (en) * | 2017-03-30 | 2021-11-04 | Marquette University | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation |
| CN112341320A (zh) * | 2020-11-02 | 2021-02-09 | 烟台丰鲁精细化工有限责任公司 | 一种对（反式-4-羟基环己基）酚的新型合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1086530A (en) | 1965-08-04 | 1967-10-11 | Du Pont | 4-phenyl and 4-substituted phenyl bicyclo[2,2,2]octane-amines |
| US3564060A (en) | 1967-12-08 | 1971-02-16 | Du Pont | Pharmaceutically active derivatives of 4 - phenyl - bicyclo (2,2,2)octane and oct-2-ene-1-carbinols and carboxaldehydes |
| DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US6288050B1 (en) | 1997-07-18 | 2001-09-11 | Duquesne University Of The Holy Ghost | Steroid sulfatase inhibitors and methods for making and using the same |
| GB9810862D0 (en) | 1998-05-20 | 1998-07-22 | Hoechst Schering Agrevo Gmbh | Substitutedn pyridine and pyrimidines, processes for their preparation and their use as pesticides |
| EP1278716B1 (en) | 2000-04-26 | 2006-08-23 | Warner-Lambert Company LLC | Trans-n-¬4-(4-hydroxyphenyl)cyclohexyl|-3-phenylpropionamide as subtype selective nmda receptor antagonist |
| JP5662803B2 (ja) * | 2007-12-20 | 2015-02-04 | アストラゼネカ アクチボラグ | Ｄｇａｔ１阻害剤としてのカルバモイル化合物１９０ |
| MX2010011408A (es) * | 2008-04-16 | 2010-12-20 | Karobio Ab | Ligandos de receptor de estrogeno novedosos. |
| AU2010209545A1 (en) * | 2009-01-28 | 2011-08-18 | Sanofi | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof |
| CN102482242B (zh) * | 2009-09-03 | 2014-07-16 | 住友化学株式会社 | 二环氧化合物、其制造方法和含有该二环氧化合物的组合物 |
| WO2012112364A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Lactam derivatives as dgat-1 inhibitors |
| WO2013119040A1 (en) * | 2012-02-07 | 2013-08-15 | Kainos Medicine, Inc. | Compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
-
2014
- 2014-11-21 AU AU2014352830A patent/AU2014352830B2/en active Active
- 2014-11-21 JP JP2016533043A patent/JP6431538B2/ja active Active
- 2014-11-21 WO PCT/US2014/066896 patent/WO2015077611A1/en not_active Ceased
- 2014-11-21 CA CA2931313A patent/CA2931313C/en active Active
- 2014-11-21 EP EP14863768.9A patent/EP3071541B1/en active Active
-
2016
- 2016-05-23 US US15/162,057 patent/US10570077B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510123A5 (enExample) | ||
| JP2017530984A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2010524932A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2016518434A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2009523760A5 (enExample) | ||
| JP2016503793A5 (enExample) | ||
| JP2013545785A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| JP2011521938A5 (enExample) | ||
| BR112014001798A2 (pt) | compostos de tetraciclina 9-aminometila substituídos | |
| JP2014505107A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| JP2015511609A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2020097577A5 (enExample) |